Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Schwenger

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Blood Cancer Discovery|May 24, 2021
An evolutionary approach to clonally complex hematologic disordersEmily Schwenger, Ulrich Steidl
Clinical Pharmacology and Therapeutics|October 25, 2017
Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of DrugsEmily Schwenger, Venkatesh Pilla Reddy, Ganesh Moorthy, et al.
Nucleic Acids Research|August 16, 2015
Functional interaction of Rpb1 and Spt5 C-terminal domains in co-transcriptional histone modificationJean Mbogning, Viviane Pagé, Jillian Burston, et al.
The Journal of Experimental Medicine|September 6, 2022
A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigmRichard T Piszczatowski, Emily Schwenger, Sriram Sundaravel, et al.
Nature Genetics|September 18, 2024
Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activitySamuel J Taylor, Jacob Stauber, Oliver Bohorquez, et al.
Cancer Cell|March 5, 2021
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanismKoki Ueda, Rajni Kumari, Emily Schwenger, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Blood Cancer Discovery|May 24, 2021
An evolutionary approach to clonally complex hematologic disordersEmily Schwenger, Ulrich Steidl
Clinical Pharmacology and Therapeutics|October 25, 2017
Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of DrugsEmily Schwenger, Venkatesh Pilla Reddy, Ganesh Moorthy, et al.
Nucleic Acids Research|August 16, 2015
Functional interaction of Rpb1 and Spt5 C-terminal domains in co-transcriptional histone modificationJean Mbogning, Viviane Pagé, Jillian Burston, et al.
The Journal of Experimental Medicine|September 6, 2022
A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigmRichard T Piszczatowski, Emily Schwenger, Sriram Sundaravel, et al.
Nature Genetics|September 18, 2024
Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activitySamuel J Taylor, Jacob Stauber, Oliver Bohorquez, et al.
Cancer Cell|March 5, 2021
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanismKoki Ueda, Rajni Kumari, Emily Schwenger, et al.
Pageof 1